- Home
- HPP vs NTLA Comparison
HPP vs NTLA Comparison
Compare HPP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- NTLA
- Stock Information
- Founded
- HPP 1997
- NTLA 2014
- Country
- HPP United States
- NTLA United States
- Employees
- HPP N/A
- NTLA N/A
- Industry
- HPP Real Estate
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HPP Finance
- NTLA Health Care
- Exchange
- HPP Nasdaq
- NTLA Nasdaq
- Market Cap
- HPP 1.0B
- NTLA 1.2B
- IPO Year
- HPP 2010
- NTLA 2016
- Fundamental
- Price
- HPP $2.40
- NTLA $11.49
- Analyst Decision
- HPP Hold
- NTLA Buy
- Analyst Count
- HPP 11
- NTLA 19
- Target Price
- HPP $3.09
- NTLA $35.11
- AVG Volume (30 Days)
- HPP 5.6M
- NTLA 4.8M
- Earning Date
- HPP 08-05-2025
- NTLA 08-07-2025
- Dividend Yield
- HPP N/A
- NTLA N/A
- EPS Growth
- HPP N/A
- NTLA N/A
- EPS
- HPP N/A
- NTLA N/A
- Revenue
- HPP $818,699,000.00
- NTLA $45,569,000.00
- Revenue This Year
- HPP N/A
- NTLA N/A
- Revenue Next Year
- HPP $5.49
- NTLA N/A
- P/E Ratio
- HPP N/A
- NTLA N/A
- Revenue Growth
- HPP N/A
- NTLA N/A
- 52 Week Low
- HPP $1.78
- NTLA $5.90
- 52 Week High
- HPP $6.09
- NTLA $26.63
- Technical
- Relative Strength Index (RSI)
- HPP 37.87
- NTLA 48.93
- Support Level
- HPP $2.41
- NTLA $12.48
- Resistance Level
- HPP $2.50
- NTLA $13.73
- Average True Range (ATR)
- HPP 0.12
- NTLA 0.89
- MACD
- HPP -0.04
- NTLA -0.24
- Stochastic Oscillator
- HPP 4.50
- NTLA 9.30
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.